Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer’s inflammatory disease pipeline with a potential, first-in-class,…
Vaisala CorporationPress releaseJanuary 27, 2026, at 10:00 a.m. (EET) Vaisala’s Financial Statement Release January–December 2025 to be published on February…